Missouri City, TXNCT07689188Now EnrollingIRB Ready

Hidradenitis Suppurativa (HS) Clinical Trial in Missouri City, TX

Access cutting-edge hidradenitis suppurativa (hs) treatment through this phase 2 clinical trial at a research site in Missouri City. Study-provided care at no cost to qualified participants.

Sponsored by Harrison Dermatology

Quick Self-Assessment

See if you qualify for this Missouri City location

Preparing your pre-screening questions…

Expert Care in Missouri City

Access hidradenitis suppurativa (hs) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hidradenitis suppurativa (hs) treatment provided free

Apply for This Missouri City Location

Check if you qualify for this hidradenitis suppurativa (hs) clinical trial in Missouri City, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Missouri City

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Missouri City site if eligible
  4. 4Begin participation

About This Hidradenitis Suppurativa (HS) Study in Missouri City

This study investigates the efficacy of topical roflumilast foam in patients with HS.

Sponsor: Harrison Dermatology

Who Can Participate

Inclusion Criteria

Male or female subjects aged 12 years or older at time of consent (or assent).
Participants and/or legal guardians are legally competent to sign and give informed consent or assent (for adolescents).
Diagnosis of Hidradenitis Suppurativa (HS) based on clinical history and physical examination for at least 3 months.
Diagnosis of HS (Hurley Stage I or II) with a total abscess and inflammatory nodule (AN) count of at least 4 to ≤10, with no draining tunnels at screening and baseline visits, affecting at least one distinct anatomical region.
Agreement to NOT use topical and systemic antibiotics and intralesional steroids for treatment of HS during the study.
Agreement to NOT use a diluted bleach bath or topical antiseptic washes containing chlorhexidine gluconate or benzoyl peroxide on the areas affected by HS lesions during the study.
Subjects who have had surgery in the treatment area must be at least 3 months post-procedure (applies to deroofing/marsupialization or excision, not incision and drainage).
Females of childbearing potential must have a negative urine pregnancy test at Screening and Baseline/Day 1 and agree to use at least one highly effective or barrier method of contraception throughout the study. Females of non-childbearing potential must be premenarchal, postmenopausal (≥12 months spontaneous amenorrhea), or surgically sterile. -In good health as judged by the Investigator based on medical history, targeted physical examination, and vital signs. Subjects and parent(s)/legal guardian(s) must be reliable and capable of adhering to the protocol and visit schedule.

Exclusion Criteria

Medical condition or physical examination abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator.
Inability to discontinue prohibited medications or treatments before Baseline or during the study.
Presence of draining tunnels at Screening or Baseline.
Unwillingness to refrain from prolonged sun exposure or tanning beds/other artificial light-emitting devices for 4 weeks before Baseline and during the study.
Skin conditions other than HS that could interfere with evaluation of study medication.
Conditions in the treatment area that could confound efficacy measurements.
Known allergy to excipients in roflumilast foam.
Use of oral roflumilast (Daxas® or Daliresp®) within 4 weeks before Baseline.
History of severe depression, suicidal ideation, or suicidal behavior at Screening/Baseline.
Pregnant, planning pregnancy during the study, or breastfeeding.
Previous treatment with roflumilast cream or foam or current roflumilast use for another indication expected to continue during the study.
Major surgery within 4 weeks before Baseline or planned during the study.
History of chronic alcohol or drug abuse within 6 months before Screening.
History of cancer within 5 years, except fully treated basal cell carcinoma, cutaneous squamous cell carcinoma, or carcinoma in situ of the cervix.
Parent(s)/legal guardian(s) or subjects unable to communicate, read, or understand the local language, or otherwise unsuitable for participation in the Investigator's opinion.
Family members of the clinical study site, study staff, sponsor, or family members of enrolled subjects living in the same household.
Known or suspected severe renal insufficiency or moderate to severe liver impairment (Child-Pugh B or C).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Missouri City?

Yes, this clinical trial (NCT07689188) has an active research site in Missouri City, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hidradenitis Suppurativa (HS) Treatment Options in Missouri City, TX

If you're searching for hidradenitis suppurativa (hs) treatment options in Missouri City, TX, this clinical trial (NCT07689188) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Missouri City research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced hidradenitis suppurativa (hs) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hidradenitis suppurativa (hs) clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Missouri City, TX

See all alzheimers disease clinical trials recruiting in Missouri City — not just this study.

Browse Alzheimers Disease Trials in Missouri City →

Browse More Trials by Condition

Alzheimers Disease TrialsRheumatoid Arthritis TrialsAtopic Dermatitis TrialsHidradenitis Suppurativa TrialsAll Conditions →

Ready to Join in Missouri City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Missouri City, TX